Corium International Inc., a Menlo Park, Calif.-based transdermal drug delivery company, has raised $25.1 million in Series C funding. Essex Woodlands Health Ventures led the deal, and was joined by Quantum Technology Partners, Aphelion Capital and an undisclosed strategic investor. Corium also has set terms with Essex Woodlands on a $15.2 million Series D round to close within the next 24 months.
In related news, Corium has agreed to merge with StrataGent Life Sciences Inc., an existing portfolio company of Essex Woodlands, Quantum Technology and Aphelion Capital. Seven Hills Partners acted as Corium's exclusive financial advisor and placement agent in these transactions. www.coriumgroup.com